Miscellaneous hormones and prostaglandins

Overgaard, 1992, Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study, Br Med J, 305, 556, 10.1136/bmj.305.6853.556 Astengo, 1994, Efficacy and safety of two elcatonin regimens in the treatment of osteoporosis, Curr Ther Res, 55, 1518, 10.1016/S0011-393X(05)80760-X Overgaard, 1990, Discontinuous calcitonin treatment of established osteoporosis: effect of withdrawal of treatment, Am J Med, 89, 1, 10.1016/0002-9343(90)90089-V Louis, 1994, Calcitonin therapy in osteoporotic syndromes, Rheum Dis Clin North Am, 20, 777, 10.1016/S0889-857X(21)00360-4 Vankrunkelsven, 1994, Salcatonin and gynaecomastia, Lancet, 344, 482, 10.1016/S0140-6736(94)91820-1 Finkelstein, 1994, Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency, New Engl J Med, 331, 1618, 10.1056/NEJM199412153312404 Mallette, 1988, Synthetic human parathyroid hormone 1–34 fragment for diagnostic testing, Am Intern Med, 109, 800, 10.7326/0003-4819-109-10-800 Price, 1993, Safety and efficacy of human growth hormone treatment in girls with Turner syndrome, Horm Res, 39, 44, 10.1159/000182768 Thomas, 1993, Long term treatment with growth hormone in Noonan's syndrome, Acta Pediatr, 82, 853, 10.1111/j.1651-2227.1993.tb17626.x Fine, 1994, Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicentre randomised double-blind placebo-controlled study, J Pediatr, 124, 374, 10.1016/S0022-3476(94)70358-2 Jorgensen, 1994, Adult growth hormone deficiency, Horm Res, 42, 241 Moxley, 1994, Potential for growth factor treatment of muscle disease, Curr Opin Neurol, 7, 427, 10.1097/00019052-199410000-00011 Riedel, 1994, Growth hormone therapy in adults: rationales, results, and perspectives, Exp Clin Endocrinol, 102, 273, 10.1055/s-0029-1211292 Malozowksi, 1993, Growth hormone insulin-like factor 1 and benign intracranial hypertension, New Engl J Med, 329, 665, 10.1056/NEJM199308263290917 Ogilvy Stuart, 1992, Growth hormone and tumour recurrence, Br Med J, 304, 1601, 10.1136/bmj.304.6842.1601 Fisher, 1988, Leukaemia in patients treated with growth hormone, Lancet, i, 1159 Butturini, 1994, Short stature, Fanconi's anaemia, and risk of leukaemia after growth hormone therapy, Lancet, 343, 1576, 10.1016/S0140-6736(94)92980-7 Czernichow, 1991, Growth hormone treatment and diabetes: survey of the Kabi Pharmacia International Growth Study, Acta Paediatr Scand, 379, 104, 10.1111/j.1651-2227.1991.tb12057.x Lamberts, 1992, The use of growth hormone in adults: a changing scene, Clin Endocrinol, 37, 111, 10.1111/j.1365-2265.1992.tb02293.x Bagge, 1993, The prevalence of radiographic osteoarthritis is low in elderly patients with growth hormone deficiency, Acta Endocrinol, 129, 296, 10.1530/acta.0.1290296 Froesch, 1994, Metabolic and therapeutic effects of insulin-like growth factor I, Horm Res, 42, 66, 10.1159/000184148 Guler, 1989, Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects, Proc Natl Acad Sci USA, 86, 2868, 10.1073/pnas.86.8.2868 Zenobi, 1992, Insulin-like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus, J Clin Invest, 90, 2234, 10.1172/JCI116109 Zenobi, 1992, Effects of insulin-like growth factor I on glucose tolerance, insulin levels, and insulin secretion, J Clin Invest, 89, 1908, 10.1172/JCI115796 Kupfer, 1993, Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously, J Clin Invest, 91, 391, 10.1172/JCI116212 Jabri, 1994, Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients, Diabetes, 43, 369, 10.2337/diabetes.43.3.369 Lieberman, 1994, Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome, J Clin Endocrinol Metab, 78, 404, 10.1210/jc.78.2.404 Froesch, 1994, Metabolic effects of insulin-like growth factor-I with special reference to diabetes, Acta Paediatr Suppl, 399, 165, 10.1111/j.1651-2227.1994.tb13317.x Lordereau-Richard, 1994, Transient bilateral papilloedema in a 10 year old boy treated with recombinant insulin-like growth factor I for growth hormone receptor deficiency, Acta Paediatr Suppl, 399, 152, 10.1111/j.1651-2227.1994.tb13314.x Ranke, 1994, Adverse events during treatment with recombinant insulin-like growth factor I in patients with growth hormone insensitivity, Acta Paediatr Suppl, 399, 143, 10.1111/j.1651-2227.1994.tb13310.x Tauber, 1994, Clinical use of the long acting somatostatin analogue octreotide in pediatrics, Eur J Pediatr, 153, 304, 10.1007/BF01956407 Oberg, 1994, Treatment of neuroendocrine tumors, Cancer Treatment Reviews, 20, 331, 10.1016/0305-7372(94)90016-7 1994, Consensus Statement: Benefits versus risks of medical therapy for acromegaly, Am J Med, 97, 468, 10.1016/0002-9343(94)90327-1 Flogstad, 1994, A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly, J Clin Endocrinol Metab, 97, 461, 10.1210/jc.79.2.461 Yaksh, 1994, Spinal somatostatin for patients with cancer: Risk benefit assessment of an analgesic, Anesthesiology, 81, 531, 10.1097/00000542-199409000-00003 Mollenholt, 1994, Intrathecal and epidural somatostatin for patients with cancer: Analgesic effects and postmortem neuropathologic investigations of spinal root and nerve roots, Anesthesiology, 81, 534, 10.1097/00000542-199409000-00004 Koop, 1994, Effect of octreotide on glucose tolerance in acromegaly, Eur J Endocrinol, 130, 581, 10.1530/eje.0.1300581 Benito, 1994, Effect of octreotide on plasma lipid metabolism on acromegaly, Ann Pharmacother, 28, 1198, 10.1177/106002809402801014 May, 1994, Octreotide dependency and headache: a case report, Cephalalgia, 14, 303, 10.1046/j.1468-2982.1994.1404303.x Robinson, 1994, Lanreotide Acetate, Drugs Future, 19, 992, 10.1358/dof.1994.019.11.272930 Marek, 1994, Long term treatment of acromegaly with the slow-release somatostatin analogue lanreotide, Eur J Endocrinol, 131, 20, 10.1530/eje.0.1310020 Scherubl, 1994, Treatment of carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide, Eur J Cancer, 30A, 1591 Sandow, 1978, Chemistry of the hypothalamic hormones, 149 Martin, 1994, Intraoperative myocardial infarction after paracervical vasopressin infiltration, Anesth Analg, 79, 1201, 10.1213/00000539-199412000-00030 Veit, 1993, Myocardial ischaemia following peritonsillar infiltration of ornipressin, Anaesthesist, 42, 320 Richardson, 1985, Desmopressin, Ann Intern Med, 103, 228, 10.7326/0003-4819-103-2-228 Beach, 1992, Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake, Clin Paediatr, 31, 566, 10.1177/000992289203100913 Humphries, 1993, Significant hyponatremia following DDAVP administration in a healthy adult, Am J Hematol, 4412 Kallio, 1993, Severe hyponatremia caused by intranasal desmopressin for nocturnal enuresis, Acta Paediatr Intern J Paediatr, 82, 881, 10.1111/j.1651-2227.1993.tb12585.x Hamed, 1993, Hyponatremic convulsion associated with desmopressin and imipramine treatment, Br Med J, 306, 1169, 10.1136/bmj.306.6886.1169 Hourihane, 1993, Use caution in prescribing desmopressin for nocturnal enuresis, Br Med J, 306, 1545, 10.1136/bmj.306.6891.1545-b Stenberg, 1994, Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents, Pediatrics, 94, 841 Matthiesen, 1994, A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis, J Urol, 151, 460, 10.1016/S0022-5347(17)34990-X Nieuwenhuis, 1988, 1-Desamino-8-d-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency, Ann Intern Med, 108, 65, 10.7326/0003-4819-108-1-65 Kyrle, 1988, IIB von Willebrand's disease: pathogenetic and therapeutic studies, Br J Haematol, 69, 55, 10.1111/j.1365-2141.1988.tb07602.x Casonato, 1994, Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease, Blood Coagul Fibrinolysis, 5, 959, 10.1097/00001721-199412000-00013 Mannucci, 1992, Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP), Br J Haematol, 82, 87, 10.1111/j.1365-2141.1992.tb04598.x Castaman, 1993, Desmopressin-induced thrombocytopenia in type 1 platelet discordant von Willebrand disease, Am J Hematol, 43, 5, 10.1002/ajh.2830430103 Barbieri, 1992, Clinical applications of GnRH and its analogues, Trends Endocrinol Metab, 3, 30, 10.1016/1043-2760(92)90089-J Crowley, 1980, The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men, New Engl J Med, 302, 1052, 10.1056/NEJM198005083021903 Bressler, 1993, Use of clonidine to treat hot flushes secondary to leuprolide or goserelin, Ann Pharmacother, 27, 182, 10.1177/106002809302700210 Vercellini, 1992, Veralipride for hot flushes during gonadotropin releasing hormone agonist treatment, Gynaecol Obstet Invest, 34, 102, 10.1159/000292736 Vercellini, 1994, Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: A controlled study, Fertil Steril, 62, 938, 10.1016/S0015-0282(16)57054-X Geisthovel, 1985, Ovarian hyperstimulation due to long term pulsatile intravenous GnRH treatment, Arch Gynaecol, 236, 255, 10.1007/BF02133944 Rizk, 1992, Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures, Hum Reprod, 7, 320, 10.1093/oxfordjournals.humrep.a137642 Tarlatzis, 1994, Follicle cyst formation after administration of different gonadotrophin releasing hormone analogues for assisted reproduction, Hum Reprod, 9, 1983, 10.1093/oxfordjournals.humrep.a138378 Matta, 1988, Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women, Clin Endocrinol, 29, 45, 10.1111/j.1365-2265.1988.tb00248.x Fogelman, 1992, Gonadotropin-releasing hormone agonists and the skeleton, Fertil Steril, 57, 715, 10.1016/S0015-0282(16)54948-6 Orwoll, 1994, Nafarelin therapy in endometriosis: Long-term effects on bone mineral density, Am J Obstet Gynecol, 171, 1221, 10.1016/0002-9378(94)90136-8 Dawood, 1994, Hormonal therapies for endometriosis: Implications for bone metabolism, Acta Obstet Gynecol Scand Suppl, 73, 22 Maillefert, 1994, Gonadotrophin-releasing hormone agonists induce osteoporosis, Br J Rheumatol, 33, 12, 10.1093/rheumatology/33.12.1199 Adashi, 1994, Long term gonadotrophin releasing hormone agonist therapy: The evolving issue of steroidal ‘add back’ paradigms, Hum Reprod, 9, 1380, 10.1093/oxfordjournals.humrep.a138715 Leather, 1993, The prevention of bone loss in young women treated with GnRH analogues with ‘addback’ estrogen therapy, Obstet Gynecol, 81, 104 Surrey, 1993, Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report, Obstet Gynecol, 81, 581 Gambacciani, 1994, Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists, Bone Miner, 26, 19, 10.1016/S0169-6009(08)80159-6 Miyagawa, 1994, Worsening of systemic lupus erythematous-associated thrombocytopenia after administration of gonadotropin-releasing hormone analog, Arthr Rheum, 37, 1708, 10.1002/art.1780371123 Barrington, 1994, Acute renal failure precipitated by luteinizing hormone releasing hormone analogue for the treatment of endometriosis, Br J Urol, 74, 672, 10.1111/j.1464-410X.1994.tb09206.x Miller, 1992, Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy, Br J Obstet Gynaecol, 99, 37, 10.1111/j.1471-0528.1992.tb13539.x